All-In · Will Ahmed with Jason Calacanis

The subscription is the strategy

Our interpretation: align recurring revenue with repeat usefulness, and test whether better data improves decisions.

Earn repeat use · 03:14

Ahmed says subscription pricing lowered the entry barrier and shifted focus from device sales to retention.

Will Ahmed’s account of WHOOP’s business model.

Continuity builds the data moat · 19:18

Ahmed reports 23.6 hours of daily wear and more than 50 billion hours of data.

Company-reported figures, not independent clinical proof. Four million members is a year-end forecast, not a current actual count.

AI needs context · 23:23

Sensors, journals and labs can add context for coaching. Predicting unmeasured biomarkers remains an ambition.

An ambition is not a claim that this capability has shipped or is clinically validated.

A pattern is not a cause · 28:24

A vitamin-D association may reflect travel or other factors. Missing comparison data limits the conclusion.

A personal-data correlation does not establish causation.

Wellness is not medical clearance · 40:15

FDA’s June 2026 closeout allowed limited non-enforcement for modified Blood Pressure Insights, not blanket clearance.

The closeout is specific to the modified BPI product, not other products, features or future modifications.

Sources:

Apple Podcasts episode and publication metadata: https://podcasts.apple.com/us/podcast/whoop-ceo-will-ahmed-50b-hours-of-health-data-a/id1502871393?i=1000798784337

Publisher audio, linked from Apple episode metadata: https://dts.podtrac.com/redirect.mp3/traffic.libsyn.com/secure/allinchamathjason/88_AUDIO_WILL_AHMED_INT.mp3?dest-id=1928300

FDA closeout letter, June 17, 2026: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/whoop-inc-709755-06172026

FDA original warning letter, July 14, 2025: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/whoop-inc-709755-07142025

Source context:

An illustrated summary of Will Ahmed’s conversation with Jason Calacanis. Episode metadata is from Apple Podcasts; regulatory context is from FDA’s primary letters. Founder statements and Podiru’s interpretation are distinguished.

Keep in mind:

Founder and company claims are attributed, not clinical proof or medical advice. Four million members is a year-end forecast, not a current count.

Correlations do not prove causes. Predicting unmeasured biomarkers remains an ambition. FDA’s limited non-enforcement for modified BPI is not blanket medical clearance.

Time anchors follow the reviewed public map’s podcast-audio references. They are not synchronized video timestamps; differently inserted ads may shift the audio.